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Abstract
Reduction of Tau protein expression was described in 2003 by Zhukareva et al. in a variant of frontotemporal lobar
degeneration (FTLD) referred to as diagnosis of dementia lacking distinctive histopathology, then re-classified
as FTLD with ubiquitin inclusions. However, the analysis of Tau expression in FTLD has not been reconsidered
since then. Knowledge of the molecular basis of protein aggregates and genes that are mutated in the FTLD
spectrum would enable to determine whether the “Tau-less” is a separate pathological entity or if it belongs
to an existing subclass of FTLD. To address this question, we have analyzed Tau expression in the frontal brain
areas from control, Alzheimer’s disease and FTLD cases, including FTLD- Tau (MAPT), FTLD-TDP (sporadic, FTLD-TDP-
GRN, FTLD-TDP-C9ORF72) and sporadic FTLD-FUS, using western blot and 2D-DIGE (Two-Dimensional fluorescence
Difference Gel Electrophoresis) approaches. Surprisingly, we found that most of the FTLD-TDP-GRN brains are
characterized by a huge reduction of Tau protein expression without any decrease in Tau mRNA levels. Interestingly,
only cases affected by point mutations, rather than cases with total deletion of one GRN allele, seem to be affected by
this reduction of Tau protein expression. Moreover, proteomic analysis highlighted correlations between reduced Tau
protein level, synaptic impairment and massive reactive astrogliosis in these FTLD-GRN cases. Consistent with a recent
study, our data also bring new insights regarding the role of progranulin in neurodegeneration by suggesting its
involvement in lysosome and synaptic regulation. Together, our results demonstrate a strong association between
progranulin deficiency and reduction of Tau protein expression that could lead to severe neuronal and glial
dysfunctions. Our study also indicates that this FTLD-TDP-GRN subgroup could be part as a distinct entity of
FTLD classification.
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Introduction
Frontotemporal Lobar Degeneration (FTLD) accounts
for 10 to 20 % of all demented cases. With an onset
usually occurring between 45 and 64 years of age,
FTLD represents the second common cause of de-
mentia in the presenile age group (<65 years of age)
[1]. FTLD is a clinical syndrome characterized by pro-
gressive deterioration in behavior, personality and/or
language. Depending on the first and prevailing symp-
toms, there are three different clinical subtypes in-
cluding the behavioral variant FTLD (bvFTLD) and
two subtypes of primary progressive aphasia: progres-
sive nonfluent aphasia (PNFA) and semantic dementia
[2, 3]. In addition, movement disorder can also be
observed in 10 to 15 % of FTLD cases (corticobasal
syndrome, parkinsonism and/or amytrophic lateral
sclerosis (ALS)) [4]. Given this phenotype variability,
FTLD clinical diagnosis remains difficult and uneasy
to establish with certainty [5]. However, genetics has
allowed for a better stratification of FTLD spectrum.
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In fact, gene mutations also play an important role in
FTLD with 30 to 50 % of patients reporting a positive
family history of FTD and 10 to 15 % of patients cor-
responding to dominantly inherited form [6]. Firstly
described are the MAPT mutations [7]. Mutations in
the progranulin gene GRN were then found to be the
most frequent mutations associated with FTLD [8, 9].
More recently, two studies demonstrated that ex-
panded hexanucleotide GGGGCC repeats in a non-
coding region of the chromosome 9 open reading
frame 72 (C9ORF72) gene was responsible for a large
proportion of both familial FTLD and ALS [10, 11].
Less frequently mutations in the valosin containing
protein (VCP) gene or charged multivesicular body
protein 2B (CHMP2B) gene are also found associated
with FTLD [12, 13].
The definite diagnosis relies on neuropathological
examination of the brain, the characteristics of these
brain lesions and their molecular basis [14]. Indeed,
as many neurodegenerative diseases, FTLD are char-
acterized by the presence of protein aggregates in the
affected brain regions. However, in contrast to the
well-characterized nature of protein inclusions (Aβ
plaques and neurofibrillary tangles) in Alzheimer’s
disease (AD), proteinaceous aggregates in FTLD can
be formed of different proteins [15]. Thus, approxi-
matively 40 % of FTLD cases display aggregates made
of abnormally and hyperphosphorylated Tau proteins
and constitute the FTLD-Tau subclass. However, most
of FTLD brains are negative for Tau inclusions and
exhibit neuronal cytoplasmic and/or nuclear inclu-
sions immunoreactive for transactive response DNA
binding protein 43 (TDP-43) and constitute the
FTLD-TDP subclass [16, 17]. This latter is subdivided
into sporadic FTLD-TDP, FTLD-TDP-GRN (patients with
mutations on GRN) and FTLD-TDP-C9ORF72 (patients
with mutations on C9ORF72) [8–11]. To a lesser extent,
another protein called FUS (Fused in Sarcoma protein) is
found in aggregates that are Tau and TDP-43 negative [18,
19]. This subclass is thus named FTLD-FUS. Finally, in-
clusions negative for Tau, TDP-43 or FUS are observed in
rare cases of FTLD and associated with ubiquitin-
proteasome system related proteins (FTLD-UPS) [20].
Prior to the discovery of the main molecular actors of
FTLD, studies described a partial or total loss of soluble or
physiological Tau protein expression in both grey and
white matter [21, 22]. This loss of Tau was originally
found in a subset of dementia called DLDH for Dementia
Lacking Distinctive Histopathology (renamed later FTLD-
ni for FTLD with no inclusion) [23]. In 2006, most of
these cases were reclassified as FTLD-U (presenting with
ubiquitin positive inclusions) [24]. However, additional in-
vestigation with specific regards to this loss of Tau expres-
sion has not been reported since Zhukareva et al. in 2003.
With the progress in genetics and neuropathology of
FTLD, the question of whether this reduction of Tau ex-
pression is seldom remains ill-defined. In this study, we
used western blot analysis to investigate human brain Tau
protein expression in Control, AD, FTLD-Tau, FTLD-
TDP-GRN, FTLD-TDP-C9ORF72, sporadic FTLD-TDP
and sporadic FTLD-FUS brains. Remarkably, we demon-
strated a huge reduction of all six human brain Tau
isoforms only in a subset of FTLD-TDP brains with muta-
tion on the GRN gene. Thus, our data clearly suggest that
these specific cases, referred to as FTLD-TDP-GRNlτ
(lτ for low levels of Tau protein), could be part of the
current classification as a distinct entity with more
severe synaptic dysfunction and astrogliosis.
Materials and methods
Frontal cortical brain tissues from Controls (n = 8), AD
(n = 8), FTLD-Tau (n = 6), FTLD-TDP-GRN (n = 10),
FTLD-TDP-C9ORF72 (n = 10), sporadic FTLD-TDP (n = 8)
and sporadic FTLD-FUS (n = 5) were provided from both
Lille Neurobank and GIE NeuroCeb in Paris. The brain
banks fulfill criteria from the French Law on biological
resources including informed consent, ethics review
committee and data protection (article L1243-4 du
Code de la Santé publique, August 2007).
Biochemical analysis
Frontal grey matter necropsic tissues (around 100 mg)
were homogenized in UTS buffer (Urea 8 M, Thiourea
2 M, SDS 2 %) using a tissue grinder Potter-Elvehjem
with a PTFE Pestle. The homogenate was further soni-
cated on ice and spun at 7500 × g during 10 min to re-
move tissue debris. The supernatant was kept at −80 °C
until use. Protein amount was determined by Bradford
protein assay, subsequently diluted in NuPAGE® lithium
dodecyl sulfate (LDS) 4× sample buffer (glycerol 40 %,
LDS 4 %, Ficoll 400 4 %, Triethanolamine chloride
800 mM, phenol red 0.025 % and Coomassie G250
0.025 %, EDTA disodium 2 mM, pH 7.6) supplemented
with NuPAGE® sample reducing agents (Invitrogen) and
loaded onto 4–12 % NuPAGE® Bis-Tris Novex Gels. Pro-
teins were transferred on nitrocellulose membrane of
0.45 μM porosity (GE Lifesciences) using liquid transfer
XCell II™ Blot Module, according to the manufacturer’s
instructions (Invitrogen). After saturation for 30 min at
room temperature with TNT (Tris 15 mM, pH 8, NaCl
140 mM, Tween 0.05 %) added with 5 % skimmed milk
powder or 5 % BSA, membranes were rinsed three times
10 min with TNT and thereafter incubated with primary
and secondary horseradish peroxidase-coupled anti-
bodies. All primary antibodies and dilutions are listed in
Table 1. The peroxidase activity was revealed using a
chemiluminescence kit (ECL, GE Lifesciences) and an
ImageQuant™ LAS4000 biomolecular imaging system
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(GE Lifesciences), according to the manufacturer’s in-
structions. Quantifications were performed using ImageJ
1.46 software (NIH Software).
Sample preparation for two-dimensional differential gel
electrophoresis (2D-DIGE)
Frozen UTS brain samples (a total of 1.5 mg of protein
for each condition) was unfrozen on ice and proteins
were precipitated using chloroform/methanol precipita-
tion [25]. The protein-dried pellet was resuspended in
UTC buffer (Urea 8 M, Thiourea 2 M supplemented
with 4 % CHAPS) and kept at −80 °C until use. Protein
concentration was measured using Quick-Start Bradford
Dye Reagent (Bio-Rad) and sample quality was evaluated
by loading 15 μg of proteins onto 4–12 % NuPAGE®
Bis-Tris Novex Gels and stained with Coomassie R-250
(Biorad).
2D-DIGE
The 2D-DIGE was performed as previously described
[25]. Briefly, 50 μg of protein was covalently coupled
with 400 pmol of cyanine dyes diluted in dimethylforma-
mide, according to the manufacturer’s instructions
(CyDIGE, GE Lifesciences). Each sample was labeled
with either Cy3 or Cy5 fluorescent dyes (GE Life-
sciences) and kept for 1 h at 4 °C in darkness. Cross-
labeling with either Cy3 or Cy5 dyes was performed in
order to avoid a preferential coupling of one cyanine to
a sample. A pool of both samples containing equal
amount of protein (50 μg in total) was labeled with Cy2
fluorescent dye and used as internal standard in accord-
ance with the manufacturer’s instructions (GE Life-
sciences). Finally, the internal standard labeled with Cy2
and the samples labeled with either Cy3 or Cy5 were
pooled and the final volume was adjusted to 350 μL by
the addition of rehydration buffer [Urea 8 M, Thiourea
2 M, CHAPS 2 %, Destreak reagent 1.1 % (GE Life-
sciences), IPG buffer pH 3–11 1.2 % (GE Lifesciences),
bromophenol blue 0.01 %]. Samples were prepared in
quadruplicate and loaded onto four independent IPG
strips. Eighteen cm long linear pH gradient of 3–11 IPG
strips (GE Lifesciences) were rehydrated overnight with
the samples in a rehydration cassette recovered with
mineral oil. Excess or mineral oil was discarded and iso-
electrofocalisation was achieved using IPGphor isoelec-
tric focusing apparatus (GE Lifesciences). A seven steps
procedure was applied with the following conditions:
150 V for 1 h, 200 V for 5 h, 200 V to 500 V step gradi-
ent for 2 h, 500 to 1000 V step gradient for 2 h, 1000 V
to 4000 V gradient for 2 h, and finally 8000 V gradient
for 2 h. Current was limited to 50 μA per strip. Strips
were then equilibrated in equilibration buffer (Urea 6 M,
SDS 2 %, Glycerol 30 %, Tris–HCl 50 mM, pH 8.6) with
successively 1 % DTT (dithiothreitol) and 4.7 % iodoace-
tamide for 15 min. Proteins were then separated in the
second dimension on 1 mm-thick 12 % SDS-PAGE gels
in an ETTAN DALTSix system (GE Lifesciences). Gels
were run at 2.5 W per gel overnight. Fluorescently la-
beled protein spots were visualized using a Typhon FLA
9500 imager (GE Lifesciences). Gels were scanned at
Table 1 Antibodies used in this study
Name Abbreviation Epitope Origin Provider Dilution Reference
Tau
Anti-total Tau (N-ter) N-ter First 19 aa in amino-terminal region Rabbit Home-made 1/10 000 [70]
Anti-total- Tau (Tau 5) Tau 5 Middle region of Tau (aa 218–225) Mouse Invitrogen 1/2 000 [71]
Anti-total-Tau (C-ter) C-ter Last 15 aa in carboxy-terminal region Rabbit Home-made 1/10 000 [72]
Synaptic proteins
α-synuclein α-syn Aa 15–123 of rat synuclein-1 Mouse BD Labsciences 1/500 [73]
Post-synaptic density 95 PSD-95 Human PSD-95 Rabbit Cell Signaling 1/1000 [74]
Munc-18 Munc-18 Aa 577–594 of rat Munc-18 Rabbit Sigma 1/10 000 [75]
Synaptophysine SYP Aa 221–313 of human SYP Mouse Santa Cruz 1/10 000 [76]
Astrocytic proteins
Glutamine synthetase GS Aa 250–350 of Human GS Rabbit Abcam 1/10 000 N/A
Glial Fibrillary Acidic Protein GFAP Bovin GFAP FL Mouse Santa Cruz 1/1000 [77]
Others
β-actin Actin N-ter Mouse Sigma-Aldrich 1/10 000 N/A
Neuron Specific Enolase NSE Aa 269–286 of Human NSE Rabbit Enzo Life Science 1/50 000 N/A
Aconitase Bovine heart mitochondria Mouse Abcam 1/1000 [78]
Histone H3 H3 C-terminus of human H3 Rabbit Millipore 1/10 000 [79]
For each antibody, the full name, abbreviation, recognized sequence, origin, provider, dilution and literature reference are given. N/A Not Available
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200 μm resolution and images were exported for further
analysis using SameSpots (TotalLab) software.
Data analysis
Spot detection and relative quantification of spot intensity
were analyzed using 2-DIGE analysis software package
SameSpots (TotalLab). One-way ANOVA statistical test
was applied and expression change was considered as sig-
nificant with an exact p-value below 0.05. Normalization
across all gels was performed using the internal standard.
Preparative 2D gels
In order to identify proteins of interest, two preparative
2D-gels with respectively 500 μg of brain protein of each
condition were performed. After electrophoresis, gels
were fixed in ethanol 30 %, orthophosphoric acid (OPA)
2 % overnight. Following washing in OPA 2 %, gels were
incubated 30 min in pre-coloration buffer (ethanol 18 %,
OPA 2 % and ammonium sulfate 0.9 M) before Coomassie
blue staining (Brillant Blue G-250, Bio-Rad) for 48 h.
Trypsin digestion, mass spectrometry and protein
identification
Spot labelling shown to be significantly different between
two conditions after SameSpots analyses was manually ex-
cised from preparative gels. Each separate spot was incu-
bated in DTT 10 mM and alkylated (iodoacetamide
55 mM) before trypsin digestion (Promega) overnight at
37 °C, according to the manufacturer’s instructions. Super-
natants, containing digested peptides, were dried using
centrifuge vacuum (Concentrator 5301, Eppendorf) and
resuspended in ultra-pure water supplemented with
trifluoroacetic acid (TFA) 0,1 %. The resulting peptide
mixture was spotted onto a MALDI plate with freshly dis-
solved α-cyano-4-hydroxycinnaminic acid (10 mg/ml in
acetonitrile 50 %, TFA 0.1 %). Mass spectrometry was
achieved with a MALDI-TOF-TOF Autoflex Speed
(Bruker Daltonics). MS and MS/MS data were ana-
lyzed with BioTools software and peptides sequences were
analyzed with Mascot (http://www.matrixscience.com/). A
mascot score above 61 was considered significant for pro-
tein identification.
mRNA extraction and quantitative real-time polymerase
chain reaction (RT-qPCR) analysis
Total RNA was extracted from the tissue of the frontal
cortex and purified using the RNeasy Lipid Tissue Mini
Kit (Qiagen) following the manufacturer’s instructions.
For each RNA sample, integrity (RIN, RNA Integrity
Number) was assessed on 2100 bioanalyzer (Agilent
Technologies, Waldbronn, Germany) using the RNA
6000 nano kit according to the manufacturer protocol.
One microgram of total RNA was reverse-transcribed
using Applied Biosystems High Capactiy cDNA reverse
transcription kit. RT-qPCR analysis was performed
using an Applied Biosystems Prism 7900 SYBR Green
PCR Master Mix. The amplification conditions were
as follows: initial step of 10 min at 95 °C, followed by
45 cycles of a 2-step PCR consisting of a 95 °C de-
naturing step for 15 s followed by a 60 °C extension
step for 25 s. Primers used were: Tau 5’UTR 5’ACAGCCA
CCTTCTCCTCCTC3’ and 5’ GATCTTCCATCACTTCG
AACTCC3’; Tau E11-12 5’ACCAGTTGACCTGAGCA
AGG3’ and 5’ AGGGACGTGGGTGATATTGT3’ and
RPLP0 5’GCAATGTTGCCAGTGTCTG3’ and 5’ GCC
TTGACCTTTTCAGCAA3’. Amplifications were carried
out in triplicate and the relative expression of target genes
was determined by the ΔΔCT method [26].
Statistical analysis
For western blot and RT-qPCR statistical analyses, the
non-parametric Mann–Whitney test or the Kruskall-
Wallis test were performed. All statistical analyses were
performed using the GraphPad Prism 6 program
(GraphPad Software) and statistical significance was set
at * p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
Results
Neuropathology
Neuropathological assessment of all cases was per-
formed in the departments of anatomo-pathology of
CHU-Lille and Hôpital Pitié-Salpêtrière. Detailed infor-
mation on pathology and demographic data are summa-
rized in Table 2.
Reduction of Tau protein expression is observed in FTLD-
TDP brains associated with GRN gene mutation without
Tau mRNA decrease
Tau protein expression was studied in all cases. We first
checked by western-blotting, if there was any Tau path-
ology in these brains, since it has been described in AD,
and a subset of FTLD-TDP patients [27, 28]. Lack of
phospho-Tau immunoreactivity was a condition to ex-
clude Tau pathology and therefore any FTLD-Tau as
compared with FTLD-MAPT and AD (data not shown).
Thereafter, Tau expression was investigated by using
antibodies targeting Tau protein independently of its
phosphorylation state to evaluate total Tau protein level.
These well-characterized antibodies either target the
amino-terminal (Tau N-ter), the median (Tau 5) or
carboxy-terminal epitope of Tau (Tau C-ter). In adult
human brain, six Tau isoforms are expressed from
MAPT gene through alternative mRNA splicing [28].
These six Tau isoforms give rise to a unique biochemical
signature made of three bands (Fig. 1a, Control patients
1 to 3). Thus, western blot analysis highlighted signifi-
cant decrease of all six Tau isoforms in eight FTLD-TDP
brains compared to control, AD and other FTLD brains
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Table 2 Demographic data on studied cases
Genetic diagnosis Cases Neuropathology Age (yr) Sex PMD (hr) RIN (a.u) Fixed hemibrain (g) Genetic variant
Controls 1 73 M 10 6,6 508
2 84 M 15,5 5,3 N/A
3 70 M 31 5,6 765
4 76 F 28 4,8 580
5 86 F N/A 5,1 540
6 79 M N/A 6,3 675
7 69 M 6 6,9 632
8 60 F 28 6,8 788
FTLD, sporadic 9 FTLD-TDP Type A 84 M 25 4,4 614
10 FTLD-TDP Type A 42 M 37 5,7 684
11 FTLD-TDP Type C 86 M 44 4,8 504
12 FTLD-TDP 67 F 22 6,3 495
13 FTLD-TDP Type C 68 M N/A 2,5 430
14 FTLD-TDP Type C 72 M 16 5,8 452
15 FTLD-TDP Type B 53 M 5 8 600
16 FTLD-TDP Type B 77 M 17 5,5 378
17 FTLD-FUS 35 M 64 5,5 N/A
18 FTLD-FUS 59 M 30 6,6 430
19 FTLD-FUS 44 M 11 5,7 504
20 FTLD-FUS 35 F 17 5,9 495
21 FTLD-FUS 54 M 18 4,8 424
FTLD, GRN 22 FTLD-TDP Type A 71 M 23 3 556 c.813_816del
23 FTLD-TDP Type A 69 F 39 3,8 370 c.1494_1498del
24 FTLD-TDP Type A 60 F N/A 3,7 200 c.1494_1498del
25 FTLD-TDP Type A 65 F N/A 5,9 N/A c.619dup
26 FTLD-TDP Type A 67 M 22 3,4 608 c.813_816del
27 FTLD-TDP Type A 69 M 18,5 7 166 c.1494_1498del
28 FTLD-TDP Type A 78 F 20 4 420 N/A
29 FTLD-TDP Type A 75 M 21 5,3 419 c.1157G > A
30 FTLD-TDP Type A 73 M 10 5,6 456 Complete deletion
31 FTLD-TDP Type A 86 F 5,5 6,8 388 Complete deletion
FTLD, C9ORF72 32 FTLD-TDP 59 M 51 6,4 N/A
33 FTLD-TDP Type B 42 M 10 3,2 N/A
34 FTLD-TDP Type B 40 F 48 4,5 N/A
35 FTLD-TDP Type B 63 M 13 5,2 762
36 FTLD-TDP 90 M 40 4,4 N/A
37 FTLD-TDP 62 M N/A 5,1 541
38 FTLD-TDP Type B 69 M 8,5 4,4 N/A
39 FTLD-TDP Type B 65 M 20 5,3 400
40 FTLD-TDP Type B 62 F 5,5 7,6 258
41 FTLD-TDP Type B 59 M 8,5 6 438
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(patients 22 to 29, Fig. 1a). Interestingly, this decrease is ob-
served with all three Tau antibodies suggesting that Tau
holoprotein isoform expression is impaired (Fig. 1a, com-
pare patient 25 with patient 33). More interestingly, this re-
duction of Tau protein expression is restricted to FTLD-
TDP brains associated with mutations on the GRN gene
(Fig. 1a and b) and not associated with other FTLD-related
gene mutations. Indeed, Tau protein expression in FTLD-
TDP-C9ORF72, sporadic FTLD-TDP or FTLD-FUS pa-
tients is rather homogeneous from one patient to another
with each antibody (Fig. 1a). Consequently to these results,
GRN cases with reduced Tau protein levels were designated
as FTLD-TDP-GRNlτ and other FTLD-TDP cases with
conserved Tau protein expression as FTLD-TDPτ.
This reduced Tau protein level could result from a lower
transcription of MAPT gene in these brains. However, RT-
qPCR using primers targeting constitutively Tau mRNA
encoded sequences [5’ UTR and exons 11–12 (E11-12)] re-
vealed no significant decrease in total Tau mRNA level
whatever the neuropathological group considered
(Additional file 1: Figure S1). Therefore, consistent
with previous data published in 2001 [21], these data
confirm a reduction in Tau protein expression that
cannot be explained by a MAPT gene trancription
modification. But more interestingly, herein we show
that this decrease in Tau protein expression is re-
stricted to patients with GRN mutations.
FTLD-TDP-GRNlτ brains display more astrogliosis and
neuronal dysfunction compared to other FTLD-TDPτ brains
Since Tau protein level is reduced but not mRNA, we in-
vestigated if other proteins could be modified. We there-
fore performed a quantitative proteomic analysis using
2D-DIGE to evaluate any dysregulation of other protein
expression. For this purpose, proteomes of FTLD-TDPτ
brains (n = 3, cases 14, 15 and 16) and FTLD-TDP-
GRNlτ (n = 3, cases 22, 24 and 25) were compared. Fol-
lowing bioinformatics assisted analysis of 2D-DIGE gels
(n = 4), 26 protein spots with significant differential level
of expression between FTLD-TDP-GRNlτ and FTLD-
TDPτ brains were isolated for further identification
(Fig. 2a, b; Table 3). According to the mass spectrometry
analysis, 20 distinct proteins including 6 isovariants of
the same protein were identified. Among the 20 proteins
identified with a significant mascot score (>61), the
amount of seven proteins decreased while that of 13 in-
creased in FTLD-TDP-GRNlτ (Table 3). Eleven proteins
which intensity varies belong to proteins involved in me-
tabolism (Table 3). Stress-related protein HSP-70.1 and
structural proteins such as Gelsolin and Neurofilament
light chain showed an increased expression (Table 3). A
decrease of UCHL1 (spot 976, −1.3 fold change), a neur-
onal enzyme involved in ubiquitinated proteins process-
ing, was also found (Table 3). Interestingly, decrease and
modification in proteins involved in synaptic function
(STXB1, DPYL2 and GLNA gene product in spot 448,
481, 689 with −1.3, −1.3 and −1.2 fold change, respect-
ively) were observed suggesting a stronger synaptic im-
pairment in the FTLD-TDP-GRNlτ group (Table 3).
Regarding glial cells, a decrease in glutamine synthetase
(GS; astrocytic enzyme involved in glutamate metabol-
ism) was observed with a −1.2 fold change, whereas the
highest fold change (+3.2) was related to four spots cor-
responding to GFAP (Table 3). Taken together, these
data demonstrate a strong correlation between reduction
of Tau protein expression, astrocytic and synaptic dys-
functions. Therefore, these proteomic data highlight
quantitative dysregulation of protein expression other
Table 2 Demographic data on studied cases (Continued)
FTLD, MAPT 42 FTLD-Tau 48 F 44,5 6,1 N/A P301L
43 FTLD-Tau 54 F N/A 7,8 N/A S305S
44 FTLD-Tau 43 M 6 4,8 N/A P301L
45 FTLD-Tau 65 F 30,5 3,4 315 P301L
46 FTLD-Tau 66 M 30 5,9 N/A P301L
47 FTLD-Tau 85 F 21 5 360 P332S
AD 48 AD 79 F 48 4,7 474
59 AD 73 F 26 4,7 460
50 AD 55 F N/A 4,8 416
51 AD 75 M 30 4,1 529
52 AD 74 M 10 3 N/A
53 AD 63 M 18 6,1 366
54 AD 61 M 23 7 414
55 AD 62 M 10 6 435
AD Alzheimer’s disease. C9ORF72, chromosome 9 open reading frame 72, FTLD FrontoTemporal Lobar Degeneration, GRN, progranulin, MAPT microtubule-
associated protein tau, PMD postmortem delay, RIN RNA Integrity Number, sp, sporadic cases. a.u arbitrary unit, N/A Not Available
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than Tau proteins in the brain from patients with FTLD-
TDP bearing GRN mutations.
Proteomic results validation in brain samples highlight
specific dysregulation in FTLD-TDP-GRNlτ brains
To validate these proteomic results found in a subset of
patients, we therefore undertook an analysis of dysregu-
lated neuronal and astrocytic proteins in all brain sam-
ples (FTLD-TDP-GRNlτ, FTLD-TDPτ and control) using
western blot analysis. We first confirmed an increase in
HSP-70 protein level in FTLD-TDP-GRNlτ cases (Fig. 3a,
b). Very strikingly, we observed as in 2D-DIGE, an up-
surge in GFAP expression in FTLD-TDP-GRNlτ group
in comparison with both control and other FTLD-TDP
cases (Fig. 3a, b). Noteworthy, GS was found to be dra-
matically decreased (Fig. 3a, b). With regards to synaptic
proteins, several synaptic markers were decreased in-
cluding α-synuclein and PSD-95 (Fig. 3a, b). These dys-
regulations found in FTLD-TDP-GRNlτ brains could be
the reflect of a global proteome deterioration in these
samples. We thus tested the level of several proteins
such as Neuronal Specific Enolase (NSE), Aconitase,
Histone H3 and Neurofilaments. Their levels remain
unchanged among the different FTLD subclasses (Add-
itional file 2: Figure S2). Finally, it is also worth noting
that among FTLD patients we could not find any
Fig. 1 Reduction of Tau protein expression in FTLD brains. a Western blot analysis of soluble Tau protein expression in control, AD and FTLD
brains using antibodies targeting total Tau independently of any post-translational modification (N-ter, Tau 5 and C-ter). Are shown representative
data from FTLD-TDP-GRN (n = 10), FTLD-TDP-C9ORF72 (n = 10), sporadic FTLD-TDP (n = 8), sporadic FTLD-FUS (n = 5), AD (n = 8) and control brains
(n = 8). b Total Tau levels were quantified and normalized to a pool containing same protein amount of each control used in this study. Both
full-length and truncated Tau species were considered for the quantification. Actin was used as loading control. Results are expressed as
means ± SEM. For statistical analysis the Kruskal-Wallis test was used (*p < 0.05, **p < 0.01; ***p < 0.001). SEM: standard error of the mean;
kDa: kiloDalton
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correlation between Tau protein decrease, macroscopic
atrophy, post-mortem delay (PMD) and RNA Integrity
Number (RIN) (Table 2, Additional file 3: Figure S3a, b,
c respectively). All these results provide further evidence
that specific dysregulations affect FTLD-TDP-GRNlτ pa-
tients such as dramatic synaptic impairment and massive
reactive astrogliosis.
Discussion
For the first time since Zhukareva’s studies, our data
clearly demonstrate that the reduced Tau protein ex-
pression is restricted to FTLD-TDP brains with muta-
tions on GRN gene. Although several FTLD brains
display a lower Tau protein level with Tau C-ter anti-
body, the labelling obtained with N-ter and Tau 5
shows a relative conservation of Tau protein expres-
sion suggesting a preferential degradation of Tau at
the C-terminal part in these cases. In contrast, FTLD-
TDP-GRNlτ brains exhibit reduced Tau levels with all
Tau antibodies tested.
Consistent with previous studies, reduction of Tau
protein expression is unlikely to result from extensive
neuronal loss as demonstrated by the preserved expres-
sion of several specific neuronal proteins [21, 22]. More-
over, we could not find any correlation between reduced
Tau level and PMD, RIN or cortical atrophy. Finally,
downregulation of MAPT transcription does not appear
to be responsible for this decrease in Tau since mRNA
level remains unchanged in these FTLD-TDP-GRNlτ
brains. Therefore, reduction of Tau protein might rather
result from post-transcriptional dysregulations.
TDP-43, the main constituent of aggregates found in
FTLD-TDP-GRNlτ cases, is involved in RNA metabolism
and especially in mRNA transport and stability through
3’UTR binding of targeted transcripts (see [29–31] for re-
view). Notably, a recent study showed that loss of TDP-43
function impairs microtubule-dependent transport of
mRNA granules towards distal neuronal compartment
[32]. Regarding axonal translation of Tau [33], loss of
TDP-43 function may lead to deficient Tau protein trans-
lation. Nevertheless, this hypothesis suggests specific
pathophysiological process in FTLD-TDP-GRNlτ when
compared to other FTLD-TDP cases that do not display
change in Tau protein level.
MicroRNAs (miRNAs) play a key role in both normal
aging and neurodegenerative diseases (see [34, 35] for
review). Interestingly, studies have reported that dif-
ferent miRNA are able to modulate Tau metabolism
[36, 37]. Among them, miR-219 is particularly inter-
esting since it modulates Tau protein translation with
relatively low influence on total Tau mRNA level.
Consistent with this study, it is worth noting that
TDP-43 is also involved in miRNA biogenesis [38],
suggesting that specific miRNA deregulation could
lead to a reduction of Tau mRNA translation in
FTLD-TDP-GRNlτ brains. Finally, emerging evidences
indicate that Tau is physiologically released into
extracellular space through multiple mechanisms such
as multivesicular body and ectosome secretion [39]. It
could therefore be interesting to evaluate Tau protein
level in cerebrospinal fluid to see if an increase in
Tau secretion participates to this reduction of Tau
protein expression.
Fig. 2 2D-DIGE analysis of FTLD-TDP-GRNlτ and FTLD-TDPτ cases. Analysis of 2D-DIGE gels was performed using TotalLab SameSpot software.
a Overlay of 2D-DIGE images with the two possible combinations. In the upper panel, FTLD-TDP-GRNlτ pool is labeled with Cy3 (green) and
FTLD-TDPτ brains with Cy5 (red). In the lower panel, FTLD-TDP-GRNlτ pool is labeled with Cy5 (red) and FTLD-TDPτ brains with Cy3 (green). In
both combination, the internal standard is labeled with Cy2 (blue). b 2D-DIGE map of proteins which are deregulated in FTLD-TDP-GRNlτ samples
compared to FTLD-TDPτ samples. Spots of interest (numbers) are listed and described in Table 3. kDa: kiloDalton; MW: molecular weight
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All FTLD-TDP-GRNlτ cases display mutation on the
GRN gene. It is well established that mutations on GRN
gene induce haploinsufficiency with approximatively
50 % reduction in mRNA levels and 33 % in protein level
[8]. However, how progranulin haploinsuffiency leads to
neurodegeneration is still unclear, in part due to the lack
of progranulin-deficient models recapitulating FTLD
hallmarks. Progranulin is a secreted protein widely
expressed throughout the body that exerts numerous
functions during development, tumor proliferation and
inflammation (see [40, 41] for review). In adult brain,
progranulin is mostly found in neurons and activated
microglia [42] where it regulates neurite outgrowth [43],
synapse biology [44], stress response [45] and lysosomal
function [46]. All these data suggest a strong role of pro-
granulin in neurodegenerative diseases but how can we
relate the reduction of Tau with GRN mutations? De-
pending on the mutation, we observed very distinct
phenotype between cases. Indeed, cases affected by a
total deletion of one GRN allele do not display any de-
crease in Tau expression whereas other point mutations
are associated with a huge reduction of all six isoforms.
This result is remarkable and suggests for the first time
that different mutations can induce distinct phenotype
and not only haploinsufficiency. Indeed, homozygous de-
letion of GRN does not lead to FTLD-TDP but to an-
other disorder called Neuronal Ceroid Lipofuscinosis
(NCL) which is characterized by lysosomal dysfunction
Table 3 Proteins differentially expressed between FTLD-TDP-GRNlτ and FTLD-TDPτ
Spot n° Protein name Accession No. Gene name p-value Fold
change
Theoretical
pI/MW
Apparent
pI/MW
Mascot
score
% sequence
coverage
308 Gelsolin P06396 GSN 0.001 +1.4 5.9/85 5.9/85 77 1.4
436 Neurofilament light polypeptide P07196 NEFL 4.57E-04 - 1.5 4.5/61.5 4.5/61.5 202 34.3
Metabolism related proteins
780 Glyceraldehyde-3-phosphate
dehydrogenase (2)
P04406 GAPDH 0.001 +1.3 8.6/36 8.4/36 63.5 21.2
1040 Ferritin light subunit P02792 FTL 3.67E-06 +2.2 5.4/20 5.4/20 354.5 30.3
738 Fructose 1.6 biphosphate aldolase P04075 ALDOA 0.0037 +1.2 9.2/39.4 9.2/39.4 81 33.5
639 Alpha-enolase P06733 ENO1 1.57E-04 +1.9 7.7/47.1 7.7/47.1 178 44.5
1033 Phosphatidylethanolamine-binding
protein 1
P30086 PEBP1 0.007 +1.3 7.4/21 8.4/21 101 56.7
956 Peroxiredoxin 6 P30041 PRDX6 1.94E-05 +1.9 6.3/25 7.0/25 147 52.2
523 Pyruvate Kinase M (2) P14618 PKM 0.019 +1.2 9.0/60 8.4/60 93.9 31.8
708 Phosphoglycerate kinase 1 P00558 PGK1 0.023 +1.2 9.2/45 9.2/45 95.2 29.5
770 N(G).N(G)-dimethylarginine
dimethylaminohydrolase 1
O94760 DDAH1 4.36E-04 +1.3 5.5/31.1 5.8/43 121 44.6
838 Guanine nucleotide-binding
protein 1
P62873 GNB1 7.02E-05 - 1.6 5.6/37 5.6/37 117 42.9
714 Creatine Kinase B P12277 CKB 0.004 - 1.2 5.2/42.6 5.6/42.6 206 54.9
Astrocytic related proteins
618 Glial fibrillary acidic protein (3) P14136 GFAP 2.43E-06 +3.2 5.3/49.8 5.5/49.8 287 56.4
689 Glutamine synthetase P15104 GLUL 0.003 - 1.2 6.5/42 7.2/42 69.4 16.4
Synaptic related proteins
476 Dihydropyrimidinase-related
protein 2 (2)
Q16555 DPYSL2 4.62E-04 - 1.3 5.9/62.3 6.6/62.3 274 50.1
448 Syntaxin-binding protein 1 (2) P61764 STXB1 3.70E-04 - 1.3 6.5/67.5 7.6/60 138 22.6
Other
883 Annexin 5 P08758 ANXA5 1.75E-04 +1.5 4.8/35.9 4.8/35.9 188 45.6
976 Ubiquitin carboxyl-terminal
hydrolase isoenzyme L1
P09936 UCHL1 0.003 - 1.3 5.2/25 5.2/25 85.8 47.1
430 Heat shock 70 kDa protein 1A P0DMV8 HSPA1A 0.002 +1.3 5.4/70 5.4/60 110 27.9
Data obtained from Samespot software are presented for each spot of interest: spot number, p-value, fold change (FTLD-TDP-GRNlτ vs FTLD-TDPτ), experimental
molecular weight (MW) and isoelectric point (pI). According to mass spectrometry identification of each protein, table also gives: the protein full name, accession
number, gene name, mascot score, sequence coverage (%), and the theoretical molecular weight (MW) and pI of the non-modified protein. A mascot score above
61 was considered as significant for protein identification. Difference between theoretical and experimental molecular weight or pI is underlined. Number of iso-
variants for each protein spot is indicated with the protein name (see parenthesis)
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[46]. Thus, a recent study has demonstrated that specific
granulins expression, resulting from progranulin extracellu-
lar cleavage, could have toxic effect [47]. These point muta-
tions could lead to modified mRNA leading to the
production of toxic granulins. However, the lack of infor-
mation on the different granulins, and their functions are
still unknown and the relationship with Tau metabolism, if
any, remains to be experimentally established.
Reduction of Tau protein expression in FTLD-TDP-
GRNlτ brains is intriguing since Tau has essential
functions in neuron. Indeed, Tau protein is a micro-
tubule associated protein (MAP) which mainly distributes
into axons [48] and was originally described as a protein
regulating the assembly and stabilization of microtubules
[49, 50], therefore modulating axonal transport [51]. How-
ever, recent studies have highlighted a role for Tau in
synaptic [52, 53] and nuclear compartments [54, 55]. Al-
though initial studies showed that tau-knockout mice de-
velop no evident pathology, probably through MAP1A
compensatory effect [56], recent studies have revealed sev-
eral pathological modifications in these knockout mice
suggesting that Tau is essential for neuronal activity [57],
iron export [58], neurogenesis [59] and both long-term
depression and long-term potentiation [60, 61]. Regarding
our results, it would not be surprising that decrease in
Tau protein expression leads to neuronal dysfunction.
This hypothesis is strengthened by our 2D-DIGE
analysis and biochemical validation, demonstrating that
expression of several neuronal proteins is either up- or
down-regulated. Indeed, both pre- and post-synaptic
proteins such as PSD-95, Munc-18, α-synuclein, synap-
tophysin and syntaxin-binding protein 1 are highly re-
duced in FTLD-TDP-GRNlτ brains in comparison to
control and FTLD-TDPτ brains. It’s interesting to note
that a very recent study has described a link between
synaptic dysfunction and progranulin deficiency [62].
Indeed, progranulin deficiency is able to induce synaptic
pruning through lysosome dysfunctions and comple-
ment activation. It could explain, in part, the dramatic
synaptic loss we found in FTLD-TDP-GRNlτ brains, in
whom progranulin levels are very low. Finally, regarding
downregulation of dihydropyriminidase-related protein 2
(DPYSL2), also called collapsin response mediator pro-
tein-2 (CRMP2), it should be noted that this protein serves
important functions in synaptic plasticity. Moreover,
CRMP2 and Tau are both high-abundance microtubule-
Fig. 3 Biochemical validation of 2D-DIGE results in control, FTLD-TDP-GRNlτ and FTLD-TDPτ brain samples. a Western blot analysis of synaptic
[PSD-95, α-synuclein (α-syn), Munc-18 and Synaptophysin (SYP)], astrocytic [GFAP and Glutamine Synthetase (GS)], and stress (HSP-70) related
protein level in control, FTLD-TDP-GRNlτ and FTLD-TDPτ brain samples. Representative data from FTLD-TDP-GRNlτ (n = 8), FTLD-TDPτ (n = 20)
and control brains (n = 8) are presented. b Protein levels were quantified and normalized to a pool containing same protein amount of each
control used in this study. Actin was used as loading control. Results are expressed as means ± SEM. For statistical analysis the Kruskal-Wallis
test was used (*p < 0.05; **p < 0.01; ***p < 0,001; ****p < 0,0001). SEM: standard error of the mean
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associated proteins, and overlap in terms of functional
regulation [63]. All these data demonstrate that synaptic
functions are impaired in these FTLD-TDP-GRNlτ brains.
In parallel with these neuronal dysfunctions, an
increase in GFAP expression is also observed in FTLD-
TDP-GRNlτ brains. GFAP belongs to intermediate fila-
ments and is expressed mostly in astrocytes. These glial
cells are complex highly differentiated cells that perform
numerous essential functions in central nervous system
(CNS), such as synaptic function and plasticity and
maintenance of the neuronal microenvironment homeo-
stasis [64]. Astrocytes respond to various forms of CNS
injury such as infections, ischemia or neurodegenerative
diseases through a process referred to as reactive astro-
gliosis and often characterized by an increase in GFAP
expression [65]. Although a mild to moderate reactive
astrogliosis represents a protective mechanism, severe
astrogliosis could lead to functional defects including
alteration of astrocyte ability to control neuronal micro-
environment homeostasis [66, 67]. Interestingly in
FTLD-TDP-GRNlτ brains, a decrease in GS expression
has been found. This astrocytic enzyme that converts
glutamate into glutamine is frequently deregulated in
neurodegenerative diseases presenting with Tau modifi-
cation [68, 69]. Thus, our results indicate that decrease
in GS may underlie glutamate homeostasis alteration,
leading to more severe failures in synaptic connectivity
and transmission in FTLD-TDP-GRNlτ brains. However,
why it is limited to cases presenting with point muta-
tions of GRN still remains unclear. Beside this, we also
found numerous deregulated proteins related to glyco-
lytic metabolism suggesting a critical role for alterations
in brain metabolism and energetics in neurodegenerative
processes. Therefore, metabolism dysregulation could re-
flect a more severe pathological state in these brains.
Conclusions
To conclude, our data reveal that reduction in Tau protein
expression is a specific feature of FTLD-TDP cases with
GRN mutation, suggesting that FTLD-TDP-GRNlτ cases
could represent a distinct subclass in the current FTLD
classification. Moreover, proteomic results clearly demon-
strate that in addition to a decrease in Tau protein expres-
sion, FTLD-TDP-GRNlτ cases also displayed astrocytic
and synaptic dysfunctions explaining more severe physio-
pathological processes. However, we are not currently able
to explain this particular feature in part due to the nature
of samples, which are post-mortem tissues, and make
these dynamic mechanisms investigation complex. If re-
duced Tau level is a consequence or an actor of deregula-
tions found in these brains remains to be determined and
will require development of both in vitro and in vivo
models. Finally, further proteomic investigations will also
help us to better characterize and understand this particu-
lar subclass of FTLD-TDP.
Additional files
Additional file 1: Figure S1. Preservation of Tau mRNA in FTLD-TDP-
GRNlτ group. qPCR analysis was done on total Tau mRNA in control and
FTLD brain samples. Both 5’UTR (Untranslated Region) and E11-12 (Exons
11–12) primers target regions present in all Tau transcripts. Data were
normalized to the mean value of control cases with Large Ribosomal
Protein P0 (RPLP0) used as reference gene. Results are expressed as
means ± SEM. For statistical analysis the Mann–Whitney test was used (ns non
significant), n= 5–10/group. SEM: standard error of the mean. (TIF 176 kb)
Additional file 2: Figure S2. Conservation of several proteins among
the different FTLD subclasses. (a) Western blot analysis of NSE (Neuron
Specific Enolase), Aconitase, Histone H3 and Heavy (NF-H) Neurofilaments
protein level in control and FTLD-U brain samples. Are shown representa-
tive data from FTLD-TDP-GRNlτ (n = 8), FTLD-TDP-C9ORF72 (n = 10), spor-
adic FTLD-TDP (n = 8), sporadic FTLD-FUS (n = 5) and control brains
(n = 8). (b) Protein levels were quantified and normalized to a pool
containing same protein amount of each control used in this study.
Actin was used as loading control. Results are expressed as means ±
SEM. For statistical analysis the Kruskal-Wallis test was used (ns non
significant). SEM: standard error of the mean. (TIF 223 kb)
Additional file 3: Figure S3. Reduction of Tau protein expression does
not result from greater post-mortem delay, aberrant RIN or cortical atro-
phy in FTLD-TDP-GRNlτ brains. (a) Fixed hemibrain weight, (b) post-
mortem delay and (c) RIN (RNA Integrity Number) of FTLD-TDP-GRNlτ,
FTLD-TDP-C9ORF72, sporadic FTLD-TDP, sporadic FTLD-FUS and control
brains. Results are expressed as means ± SEM. For statistical analysis the
Kruskal-Wallis test was used (*p < 0.05; ns non significant). a.u arbitrary
unit, SEM: standard error of the mean. (TIF 164 kb)
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